semaglutide for binge eating disorder on The rapid rise of GLP-1 receptor agonists presents a complex dilemma GLP-1 Therapy: An Emerging Tool

Drucker has also found evidence that GLP-1 may improve cognitive function and protect against neurodegenerative diseases, which contributes to healthy aging and a longer life

Certain features warrant prompt medical evaluation: Severe muscle pain or weakness , particularly if accompanied by dark urine, which may indicate rhabdomyolysis (a rare but serious condition involving muscle breakdown) Joint swelling, redness, or warmth , which could suggest inflammatory arthritis or infection (septic arthritis) Pain that significantly impairs daily activities or does not respond to simple analgesia Systemic symptoms such as fever, unexplained weight loss (beyond expected therapeutic effect), or night sweats New or worsening pain following dose escalation, which may require dose adjustment or further investigation Sudden, severe pain in the right upper abdomen , possibly with fever or jaundice, which could indicate gallbladder disease (a recognised risk with GLP-1 receptor agonists) [1] [5] Patients should also seek advice if they experience other concerning adverse effects of Ozempic, including: Persistent nausea or vomiting leading to dehydration or reduced fluid intake Symptoms of hypoglycaemia (tremor, sweating, confusion), particularly if taking Ozempic with insulin or sulphonylureas Severe abdominal pain, which may indicate pancreatitis (a known but uncommon risk with GLP-1 receptor agonists) [1] [5] Visual changes or signs of diabetic retinopathy progression For urgent concerns outside of GP hours, patients should contact NHS 111

Their findings, which were published in the journal Antioxidants , suggest supplementing those who test positive for COVID-19 with a combination of glutathione precursors (which was shown in previous research to improve these levels, along with reducing inflammation) may be an effective treatment

Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: a randomized controlled trial